<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035671</url>
  </required_header>
  <id_info>
    <org_study_id>FRD02</org_study_id>
    <nct_id>NCT01035671</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia</brief_title>
  <official_title>A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penwest Pharmaceuticals Co.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penwest Pharmaceuticals Co.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a double-blind, placebo-controlled study with two dose levels of A0001 given
      twice daily for 28 days. Potential subjects will be screened first to determine eligibility,
      after which they will be randomized to receive either a high dose of A0001, a low dose of
      A0001 or placebo for 28 days.

      Eligible subjects will return within 21 days of screening for the baseline visit and
      randomization to one of three potential treatments. The subjects will be required to take 3
      capsules of study medication in the morning with a morning meal and 3 capsules of study
      medication at night with an evening meal for 28 days. Additional visits to the clinic are
      planned for Day 14 and Day 28, at which time a number of clinical and biochemical assessments
      will be done.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Disposition Index of Glucose Regulation, determined by Frequent Sampling IV Glucose Tolerance Test</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity index (SI) calculated from IVGTT</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose effectiveness (SG) calculated from IVGTT</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AIRg for glucose and insulin during IVGTT</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose, Insulin and Lactate</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 1,5-anhydroglucitol (1,5-AG) (Glycomark)</measure>
    <time_frame>Baseline, Day 14 and Day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Activity of Complex 1 in whole blood</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25 Foot Walk Test</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FARS/neurological exam</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-Hole Peg Test</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision Low Contrast Letter Acuity Test</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Clinical Severity</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36Â®</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A0001 (0.5 g BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A0001 (0.75 g BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-tocopherolquinone (A0001)</intervention_name>
    <description>28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-tocopherolquinone (A0001)</intervention_name>
    <description>28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>28 days of placebo oral capsules. Treatment taken twice daily with meals.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with genetically confirmed Friedreich's Ataxia (GAA or point mutation)

          -  Impaired Glucose Tolerance, measured by Oral GTT

        Exclusion Criteria:

          -  Overt Diabetes Mellitus

          -  Presence of clinically significant cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lynch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>April 21, 2011</last_update_submitted>
  <last_update_submitted_qc>April 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Sciascia, MD/Chief Medical Officer and VP Clinical Operations and Regulatory Affairs</name_title>
    <organization>Penwest Pharmaceuticals Co.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocopherylquinone</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

